Dual Antiplatelet Therapy vs. Aspirin After CABG in ACS Patients
- Dual antiplatelet therapy (DAPT) did not demonstrate superior efficacy to aspirin alone in preventing major adverse cardiovascular events (MACE) and significantly increased major bleeding risk in patients with...
- Current ESC guidelines recommend DAPT - aspirin combined with a P2Y12 inhibitor - over single antiplatelet therapy for patients with ACS who have undergone CABG.
- To address this evidence gap, researchers conducted the TACSI (Ticagrelor versus aspirin in Coronary Surgery Intervention) trial.The trial investigated whether 12 months of DAPT,utilizing ticagrelor and aspirin,would be...
“`html
DAPT No More Effective than Aspirin Alone after CABG for Acute Coronary Syndrome
Dual antiplatelet therapy (DAPT) did not demonstrate superior efficacy to aspirin alone in preventing major adverse cardiovascular events (MACE) and significantly increased major bleeding risk in patients with acute coronary syndrome (ACS) undergoing coronary artery bypass grafting (CABG). These findings, presented at ESC Congress 2025 and published concurrently in the New England Journal of Medicine, challenge current European Society of cardiology (ESC) guidelines.
Background: Current Guidelines and Evidence Gaps
Current ESC guidelines recommend DAPT - aspirin combined with a P2Y12 inhibitor – over single antiplatelet therapy for patients with ACS who have undergone CABG. Though,these recommendations have largely been based on extrapolations from studies not specifically focused on CABG patients,sub-analyses of larger ACS trials,and smaller randomized studies utilizing surrogate endpoints. A significant gap existed in robust data from large-scale randomized trials evaluating clinically relevant outcomes in this specific population.
The TACSI Trial: Design and Methodology
To address this evidence gap, researchers conducted the TACSI (Ticagrelor versus aspirin in Coronary Surgery Intervention) trial.The trial investigated whether 12 months of DAPT,utilizing ticagrelor and aspirin,would be more effective than aspirin alone in preventing MACE in ACS patients who had undergone CABG. The study was a randomized, double-blind, placebo-controlled trial.
Key details of the TACSI trial include:
- Participants: Patients with ACS undergoing CABG.
- Intervention: 12 months of DAPT (ticagrelor 90mg twice daily + aspirin 75-100mg daily) versus aspirin alone (75-100mg daily).
- Primary Endpoint: A composite of cardiovascular death, stroke, or myocardial infarction.
- Secondary Endpoint: Major bleeding events (defined according to the Bleeding Academic Research Consortium criteria).
Key Findings: DAPT Increases Bleeding Risk Without Benefit
the results of the TACSI trial revealed that DAPT was not associated with a statistically significant reduction in MACE compared to aspirin alone. Furthermore, DAPT significantly increased the risk of major bleeding events. specifically:
| Endpoint | Aspirin Alone (%) | DAPT (%) | hazard Ratio (95% CI) | p-value |
|---|---|---|---|---|
| MACE (Cardiovascular Death, Stroke, MI) | [Data to be added from source] | [Data to be added from source] | [Data to be added from source] | [Data to be added from source] |
| Major Bleeding | [data to be added from source] | [Data to be added from source] | [Data to be added from source] | [data to be added from source] |
Note: Specific data points for the table will be populated upon access to the full New England Journal of Medicine publication.
Implications for Clinical Practice
These findings have significant implications for the management of